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Introduction
Wound repair involves a complex series of interactions among cells, cytokines, and the extracellular matrix (ECM). The response of the injured dermis has been extensively studied and includes an early phase of coagulation, inflammation, and cell migration, and a subsequent phase characterized by cell proliferation, angiogenesis, ECM synthesis, and remodeling (Falanga et al., 1988) . Many studies have demonstrated that Types I and 111 collagen provide structural support for the dermis in wound repair (Haukipuro et al., 1991; Uitto et al., 1989; Gay et al., 1978) . Others have shown that noncollagenous ECM proteins, e.g.. fibronectin, tenascin, and syndecan, are expressed at high levels in healing wounds. During wound repair, fibronectin facilitates the migration of cells (Clark, 1988; Donaldson and Mahan, 1983) . and syndecan is important in cell adhesion and binding of growth factors (Elenius et al.. 1991) . Migration of the epidermis induces synthesis of tenascin in the dermis (Chuong and Chen, 1991; Mackie et al., 1988) , but the functional 
SPARC "A.
In contrast, immunoreactivity for TSP-1 was extraceflular; expression at the wound edge was noted at 12 hr and was maximal at 1-2 days. TSP-1 mRNA was found in the thrombus, but not at the wound edge. In conclusion, SPARC and TSP-1 have contrasting roles during wound healing. SPARC expression from the middle through late stages of repair was consistent with its previously proposed functions in remodeling; in contrast, the transient expression of consequences of this expression are not clear. Little is known about the role of other ECM proteins in wound repair. Ptevious studies of SPARC and TSP-1 have demonstrated that these glycoproteins are structurally distinct but are expressed by many of the same types of cells in culture and in tissues. In addition, SPARC apd TSP-1 have similar as well as contrasting properties in vitro (for review see Sage and Bomstein, 1991) . Because of their presence in platelet a-granules and the potential for additional synthesis at sites of tissue injury, comparison of these proteins and their potential functions in vivo is of interest in the study of wound repair. SPARC (Secreted Protein, Acidic and Rich in Cysteine) is a Ca2+-binding glycoprotein secreted by many cells, e.g., endothelial cells, fibroblasts, osteoblasts, and platelets (Kasugai et al., 1991; Vuorio et al., 1991; sage et al., 1989a; Stenner et al. 1986 ). It exhibits affinities for components of the ECM including Type I collagen and thrombospondin and is co-expressed with Type I collagen in fibroblasts (Salonen et al., 1990; Sage et al., 1989b; Cletardin et al., 1988) . SPARC is anti-adhesive for endothelial cells and fibroblasts in vitro (for review see Sage et al., 1992; Sage and Bornstein, 1991) . In vivo, SPARC is expressed in tissues that exhibit high rates of cell proliferation and remodeling or renewal (i.e., skin, gut, embryonic mesenchyme) (Sage et al., 1989~) . Although no studies are available on its distribution in wound repair, the affinity of SPARC for Type I collagen and the expression of SPARC in tissues that undergo high rates of morphological change and remodeling suggest a role in reparative processes.
Thrombospondin 1 (TSP-1) was the first member of what is now recognized to be a family of at least four unique genes (for review see Bornstein, 1992) . These proteins for the most part exhibit a distinct distribution in embyronic mouse tissues and therefore are likely to have different functions (hela-Arispe et al., in press). TSP-1 is a secreted, trimeric glycoprotein which, like SPARC, is found in endothelial cells, fibroblasts, and a-granules of platelets (Jaffe et al., 1983; Raugi et al., 1982; McPherson et al., 1981; Lawler et al., 1978) . Together with SPARC and tenascin. TSP-1 has anti-adhesive properties in vitro (for review see Sage and Bomstein, 1991) . TSP-1 decreases the number of focal adhesions produced by endothelial cells (Murphy-Ullrich and Hook, 1989) and permits attachment, but not spreading, of endothelial cells, epithelial cells, and smooth muscle cells (Lawler et al., 1988) . In contrast, it has been described as an adhesive protein for other cell types such as keratinocytes, platelets, and certain tumor cells (for review see Sage and Bornstein, 1991) . BP-1 is reported to facilitate the growth of smooth muscle cells and fibroblasts (Phan et al., 1989; Majack et al., 1986) , whereas it inhibits both the growth of endothelial cells and angiogenesis in vitro and in vivo (hela-Arispe et al., 1991a; Baganvandoss and Wilks, 1990; Good et al., 1990) . TSP-1 is also present in tissues that display rapid cell growth and differentiation in vivo (i.e., skin) and has been detected in embryonic tissues during morphogenesis and organogenesis (Iruela-Arispe et al., in press; O'Shea and Dixit, 1988) . In a study of human incisional wound healing, TSP protein (presumably TSP-1) was seen initially at the wound edges and in perivascular tissue at later stages of repair (Raugi et al., 1987) . A study of TSP-1 mRNA in wound repair has not been published. Moreover, the existence of other thrombospondins has only recently been appreciated.
Prior studies of SPARC and TSP-1 have demonstrated significant roles for these proteins in processes that require highly integrated interactions between cells and the ECM. In this study we determined, by immunohistochemistry and in situ hybridization, the temporal and spatial distributions of SPARC and TSP-1 in repair of rat dermal wounds. Despite a similar distribution of these proteins in cells and in tissues, their expression during wound repair was different. The presence of SPARC mRNA and protein at the wound edge and in the newly formed tissue from the middle through late phases of repair was consistent with a role in remodeling. The transient appearance of TSP-1 protein early in wound repair and its lack of synthesis by cells associated with the wound edge indicated a role in early stimulation of proliferation and establishment of a provisional matrix for wound repair.
Materials and Methods
Experimental Wound Model. Adult male Sprague-Dawley rats (250 g) were handled according to the guidelines of jhe American Association for Accreditation of Laboratory Animal Care and the Bristol-Myers Squibb Animal Care Committee. The rats were anesthetized with a single IM injection of ketamine (40 mglkg). The dorsum was shaved and cleaned with isopropyl alcohol. Full-thickness linear incisions (4 cm long) through the skin to the l e d of the adipose tissue were placed on either side of the midline with a #lo sterile surgical scalpel (Feather Safety Razor; Tokyo, Japan), as described by Mustoe et al. (1987) . The wounds were coapted with two sutures and therefore healed by primary intent. After surgery the animals had free access to food and water. To prevent disturbance of wounds, animals were fitted with plastic neck collars. Animals were sacrificed by an overdose of pentobarbital. Wounds were biopsied at 12 hr and at 1, 2, 3, 5 , 7, and 14 days. For immunohistochemistry, wound tissues were fixed in methyl Carnoy's (60% methanol, 30% chloroform, 10% acetic acid), embedded in paraffin, and cut into 5-pm sections. For in situ hybridization, wound tissues were fixed in 4% paraformaldehyde (PFA) (pH 7.4). embedded in paraffin, and sectioned as above. To ensure adequate sampling, wounds were obtained from two or three separate animals for each timepoint.
Histological Analysis of Wound Healing. Five-pm sections stained with hematoxylin and eosin were analyzed with a Zeiss photomicroscope I1 equipped with universal and darkfield condensers.
Characterization of Anti-SPARC and Anti-TSP1 Antibodies. Two independent rabbit anti-SPARC antibodies were used for immunohistochemical localization of SPARC protein. The first antiserum was produced against purified murine SPARC (Sage et al., 1989b) ; the second was produced against a synthetic peptide that represented amino acids 16-35 of the mature protein. IgG fractions from each antiserum were purified by affinity chromatography on SPARC or on peptide linked to Sepharose (Pharmacia; Piscataway, NJ) as described by Lane and Sage (1990) . The titer and specificity of each antibody were assessed by ELISA. No crossreactivity with other proteins was noted, and anti-SPARC reactivity was completely eliminated when the antibodies were pre-absorbed with solubilized antigen.
The anti-TSP-1 antibodies were produced in a rabbit against intact human platelet TSP-1. The IgG fractions from the antisera were affinity-purified and tested for specificity as previously described (hela-Arispe et al., 1991a) .
Anti-Type I collagen antisera against lathyritic rat skin Type I collagen were produced in a guinea pig. Titer and specificity were determined by ELISA and by immunoblot analyses of purified antigen and of conditioned media from cultured human fibroblasts (unpublished observations).
Cell Culture and Protein Puritication. Murine SPARC was purified from conditioned medium (CM) of the PYS-2 cell line by a standard protocol (Sage et al., 1989b) . A rat fibroblast cell line (Rat-1) was used to verlfv crossreactivity of the anti-murine SPARC IgG with rat proteins. Cells were grown in Dulbecco's modified Eagle's medium (DMEM) (Gibco; Grand Island, NY) supplemented with 10% fetal calf serum (FCS) (Hyclone; Logan, UT), 250 pglml amphotericin, 100 U/ml penicillin G. and 100 Ulml streptomycin sulfate (Sigma; St Louis, MO). For analysis of secreted proteins, cells were grown to 80% confluency and washed with serum-free medium. CM was prepared by incubation of cells under serum-free conditions for 24 hr. CM was clarified of cell debris by centrifugation, and protease inhibitors were added to a final concentration of 0.2 mM phenylmethylsulfonyl fluoride and 5 mM N-ethylmaleimide. Proteins from CM were concentrated by centrifugation dialysis with Centricon-10 microconcentrators (Amicon; Beverly, MA).
ELISA and Immunoblotting. ELISA for SPARC or synthetic peptides and immunoblotting were performed as previously described (Lane et al., 1990; Sage et al., 1989~) . Radiolabeled antigen-antibody complexes were detected by autoradiography.
Immunohistochemistry. Paraffin sections were mounted on glass slides overnight at 40°C and prepared for immunohistochemistry as previously described (Sage et al., 1989~) . Sections were incubated with one of the following: (a) an affinity-purified rabbit polyclonal antibody against intact murine SPARC protein (anti-SPARC) at 10 pglml; (b) an affinity-purified rabbit polyclonal antibody against amino acids 16-35 of murine SPARC (anti-SP[l6-35]) at 2.5-5 pg/ml; (c) a monoclonal antibody against a cytoplasmic component of cells that belong to the mononuclear phagocyuc system (ED-1) at 1.5 pglml (Serotec; Oxford, UK); (d) an affinity-purified rabbit antibody against human platelet thrombospondin (anti-TSP-1) at 0.25 pglml; (e) guinea pig antiserum against rat Type I collagen; or (f) biotinylated Gzffonia (Bandeiraea) simplicifolia lectin (BSLB4) (Coffin et al., 1991) at 10 pglml (Vector; Burlingame, CA). paraffin sections of 17-day whole mouse embryos were used as positive controls for SPARC and TSP-1. Pre-immune antisera and secondary antibody alone served as negative controls. After three 5-min washes in PBS, sections incubated with anti-SPARC, anti-TSP-1, and anti-Type I collagen antibodies were exposed to biotinylated goat antibodies against rabbit or guinea pig IgG at 7.5 pglml (Vector) or, for ED-1, biotinylated goat antibodies against m o w IgG, affinity-purified and pre-adsorbed with rat serum, at 2.5 pglml (Vector). Immune complexes were identified with an avidin-biotin-peroxidase reaction system (Vector) as previously described (Sage et al., 1989~) . Sections were rinsed, counterstained with toluidine blue, dehydrated with a graded series of ethanol (70-loo%), cleared with xylene, and mounted with Permount (Fisher; Fair Lawn, NI). Sections were photographed with a Zeiss photomicroscope.
To analyze relative SPARC expression we used a computerized image analysis system equipped with the Optima program (Bioscan; Edmonds, WA) that permitted quantitation of the optical density of the peroxidase reaction product. The proportion of fibroblastic cells positive for SPARC (as compared with the total number of fibroblastic cells) was calculated as a function of distance from the wound edge at each time point. Fibroblastic cells were defiied by characteristic morphology, location, immunoreactivity with antisera against Type I collagen, and absence of reactivity to BSLB4 lectin. Immunostain for TSP-1 did not correlate with cell boundaries and appeared as a uniform reaction product associated with the ECM. Therefore, to analyze relative TSP-1 expression, we used the same computerized system to calculate an average intensity of extracellular reaction product as a function of the distance from the wound edge at each time point.
Synthesis of Riboprobes. Riboprobes were transcribed with an RNA transcription kit (Promega; Madison, WI) in the presence of u-[~%]-~UTP (Amersham; Arlington Heights, IL). The specific activity of probes was approximately 3-4 x 10' cpmlpg. The SPARC riboprobe was transcribed from a 1147 bp BamHIlHindIII mouse cDNA fragment, cloned in an antisense orientation relative to the SP6 promoter in a pGEM-1 vector. Before use the SPARC riboprobe was hydrolyzed to less than 150 BP fragments by alkaline hydrolysis as described by Cox et al. (1984) . The Type I collagen riboprobe was transcribed from a 300 BP EcoRIlHindIII mouse cDNA fragment of a (1) I collagen, cloned in an anti-sense orientation relative to the T3 promoter in a PBS M13 vector. The TSP-1 riboprobe was transcribed from a 294 BP BglIIlPst I mouse TSP-1 cDNA generated by the polymerase chain reaction and cloned in a PBS M13 vector in an anti-sense orientation relative to the T3 promoter. The respective riboprobes transcribed in a sense orientation were used for control experiments.
In Situ Hybridization. The in situ hybridization protocol was a modification of a method described by Holland et al. (1987) . Sections were mounted overnight on Probe-On slides (Fisher; Pittsburgh, PA), hydrated with a graded series of ethanol (solutions of 100-70%). rinsed in PBS, post-fixed with 4% PFA for 20 min, rinsed in PBS, and digested for 2-3 min with proteinase K (BRL; Gaithersburg, MD) (2.5 pglml in 50 mM Tris-HCI with 5 mM EDTA). Samples were rinsed with PBS, fixed with 4% PFA for 5 min. dipped in water treated with diethylpyrocarbonate (DEPC-water), exposed to 0.1 M triethanolamine (pH 8) with 0.05% (vlv) acetic anhydride for 10 min, rinsed in PBS for 5 min. dipped in DEPC-water, dehydrated in graded solutions of ethanol (70-100%). and air-dried. Sections were then treated overnight at 50°C in pre-hybridization solution [0.6 M NaCI, 0.12 M Tiis-HC1 (pH 8), 8 mM EDTA, 0.02% Ficoll 400, 0.02% polyvinylpyrrolidone, 0.1% Pentex BSA (Sigma), 500 pglml salmon sperm DNA, 600 pglml yeast total RNA, and 50% deionized formamide]. The samples were hybridized at 50'C overnight in pre-hybridization solution that contained 10% dextran sulfate and 0.1 Irglml of the SPARC or the Type I collagen anti-sense and sense riboprobes, or 0.2 pglml of the TSP-1 anti-sense and sense riboprobes. Five-pm sections of 14-and 16-day mouse embryos were used as positive controls for the TSP-1 anti-sense riboprobe. Samples were washed for 30 min at 50'C in formamide buffer (50% formamide, 5% 20 x SSC (1 x SSC is 0.15 M NaCI, O.015M Na-citrate (pH 7.5). 1% 1M MT in DEPC-water), for 30 min at room temperature in 0.5 x SSC, and for 30 min at 37'C in 3.5 x SSC with 40 pglml RNAse A (Sigma) and 50 p1 RNAse T1 (Sigma). Slides were incubated sequentially in 3.5 x SSC for 10 min at room temperature and 0.1 x SSC for 90 min at 65°C. Sections were 'dehydrated with ethanol (solutions of 50, 70, 95, and 100%) containing 0.3 M sodium acetate and were subsequently air-dried. We performed autoradiography with NTB 3 emulsion (Kodak; Rochester, NY) diluted to 40% with a solution of 4% Dreft detergent; slides exposed for 5-7 days at 4'C (SPARC and Type I collagen) and 12-14 days (TSP-1) were developed in Kodak D-19 developer and fixed in GBX fixer (Kodak). Samples were counterstained with methyl green, dehydrated with ethanol (solutions of 70-100%). cleared in xylene, and mounted with Permount. Sections were photographed with a Zeiss photomicroscope.
Combined In Situ Hybridization and Immunohistochemistry. A combination of in situ hybridization and immunohistochemistry was performed by a modification of the method of Sollberg et al. (1991) . Sections were prepared for pre-hybridization as described but were subsequently prehybridized, hybridized (with the SPARC or TSP-1 riboprobe), and washed in the same manner as described in the section above for routine in situ hybridization. After 90 min in 0.5 x SSC at 65"C, sections were rinsed twice in PBS and blocked for 1 hr at 21' C with PBS containing 1% goat serum and 0.5% BSA. Immunohistochemistry was performed as described above. After the avidin-biotin-peroxidase reaction, sections were rinsed three times in tapwater, dehydrated in ethanol (50.70.95, and 100%) containing 0.3 M sodium acetate, air-dried, and dipped in "73-3 emulsion.
Results

Histological Analysis of Wound Healing in Rats
Wound repair in the rats occurred rapidly, with closure of the epidermis before Day 3 as determined by macroscopic inspection. Wounds that became infected were excluded from the studies. Microscopic analysis confirmed early closure and re-epithelialization of the wounds at Day 3. By Day 5 there was evidence of active tissue repair including increased cellularity (macrophages, fibroblasts, endothelial cells), collagen synthesis, and angiogenesis in the dermal compartment of the wound. At 10-14 days the wound area was occupied by aligned fibroblasts and collagen bundles (data not shown).
Cbaracterization of Anti-SPARC Antisera
Rabbit antisera were produced with purified murine SPARC or with synthetic peptides that represented specific regions of the amino acid sequence. Antisera were affinity-purified and characterized by ELISA ( Figure 1A ) and immunoblots ( Figure 1B) . The antibody against the intact protein (anti-SPARC) recognized only SPARC. The antibody against a peptide representing amino acids [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ) recognized both the peptide and the intact protein (Figure 1A) . In immunoblots both antibodies recognized a single protein of 43,000 MW from the conditioned medium of Rat-1 fibroblasts (Figure 1B -27
The expression of SPARC protein and mRNA in cells and at the wound edge was studied by immunohistochemistry and in situ hybridization. Figure 2 illustrates SPARC immunoreactivity at the wound edge from 12 hr to 14 days with anti-SP[l6-35] (Figures  2a-2f ). Identical immunohistochemical results were obtained with the antibody against intact SPARC (data not shown). Normal dermis (Figure 2g ) contained fibroblastic cells that stained positively for SPARC at all timepoints. At 12 hr (Figure 2a ) no immunoreactivity was detected at the wound edge or in the thrombus. Expression of SPARC protein in the wound was noted first at 2 days ( Figure  2b ). The immunoreactivity was intracellular and was found predominantly in fibroblastic cells (defined as cells confined to the dermis with morphological characteristics of fibroblasts). Fibroblastic cells exhibited immunoreactivity with antisera against Type I collagen and did not stain with BSLB4 lectin, a marker for non-primate endothelial cells (Coffin et al., 1991) . or with ED-1, a marker specific for macrophages (data not shown). Inflammation, determined by the presence of leukocytes and macrophages, was maximal at 3 days. At this same timepoint the number of SPARC-positive cells relative to the total number of fibroblastic cells at the wound edge was increased (Figure 2c ). By 5 days (Figure 2d ) expression of SPARC was noted in many fibroblastic cells concentrated in newly formed tissue of the healing dermis; this localized increase in immunoreactivity was maximal at 7 days (Figure 2e ) and continued through Day 14 (Figure 2f) . Figure 4 and 14 days (a-1, respectively) and exposed to anti-SP [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . The brown reaction product represents immunostain for SPARC protein. At 12 hr (a) and 2 days (b) there was no immunostain for SPARC at the wound edge (white arrows), but many fibroblastic cells in the normal dermis expressed SPARC (black arrows, a). At 3 days (c) there was increased immunoreactivity for SPARC protein at the wound edge (white arrows). The immunostain (white arrows) increased at 5 days (d) and was maximal at 7 days (e). At 14 days (1) the localized cell staining in the area had disappeared and many cells throughout the dermis reacted positively with the antibody. The immunoreactivity for SPARC in the injured dermis at 14 days (black arrows, f) was greater than that in the normal dermis (black arrows, (areas are defined in the cartoon at the lower righthand corner of Figure 4 ). There was a lack of cells positive for SPARC at the wound edge at 12 hr, 1 day, and 2 days. At 3 days the number of these cells increased at the wound edge, with a relative paucity of cells positive for SPARC in the dermis adjacent to the wound site (e.g., Area 2). The maximal number of fibroblastic cells that expressed SPARC at the wound edge was noted at 7 days. As a result of cell proliferation in the injured dermis, the proportion of cells positive for SPARC in Areas 2 and 3 (adjacent to the wound edge) increased from Day 5 and persisted through Day 14. The proportion of positive cells in areas beyond Area 3 appeared identical to normal dermis, as depicted in Figure 2g , and was not examined further. Neither the antibody against the whole molecule nor against the peptide revealed immunoreactive cells in epidermis, hair follicles, or glands. Endothelial cells and smooth muscle cells in many of the capillaries (open arrow) and arterioles (arrowhead) of the dermis and granulation tissue were positive for SPARC at all timepoints (Figure 2h) ; these cell types were not included in the quantitative analysis. Endothelial cells also exhibited reactivity for BSLB4 lectin and Type VI11 collagen (data not shown).
In situ hybridization for SPARC mRNA in the wounds produced results consistent with those obtained by immunohistochemistry for SPARC protein. Figures 5a-5f illustrate the expression of SPARC mRNA in wound repair from 1-14 days. In all photos the epidermis is on the left and the wound edge is in the center. At early timepoints we detected expression of SPARC mRNA in the thrombus as noted in the photograph at 1 day (Figure 5a) . At 1-2 days (Figures 5a  and 5b ) SPARC mRNA was present in both fibroblastic and endothelial cells in the dermis but there was no detectable expression at the wound edge. The signal at the wound edge first appeared at 3 days and was largely localized to fibroblastic cells (Figure 5c ). By immunohistochemistry and in situ hybridization there was a paucity of SPARC expression in dermis near the wound edge before this timepoint. Expression of SPARC mRNA at the wound site steadily increased up to 7 days (Figure 5e ); by Day 14 (Figure 5f ) the concentration of mRNA was localized less to the wound edge and appeared more diffuse throughout the dermis.
Because of the affinity of SPARC for Type I collagen and the co-expression of these proteins in fibroblasts, especially in certain connective tissue diseases (Vuorio et al., 1991; Salonen et al., 1990) , we performed immunohistochemistry and in situ hybridization concurrently for Type I collagen. Figure 7 illustrates the expression of a (1) I collagen mRNA at the wound edge at 1, 5, and 14 days. The spatial and temporal expression of Type I collagen mRNA at the wound edge was concordant with the expression of SPARC mRNA, with the exception that Type I collagen mRNA was absent from the clot at the wound edge at Day 1 (Figure 7a ). There was also constitutive expression of Type I collagen in fibroblastic cells throughout the normal dermis and an increase in expression as fibroblasts aligned in the newly formed tissue at 5 days (Figure 7b ). By Day 14 ( Figure 7c ) the expression of Type I collagen mRNA was localized less to the wound edge and appeared more diffuse throughout the dermis. Consistent results were obtained with immunohistochemistry for Type I collagen in the wounds (data not shown).
We performed a combination of in situ hybridization and immunohistochemistry with the SPARC riboprobe and ED-1, a macrophage-specific antibody. ED-1-positive cells were first seen at 1 day and were maximal in number at 2-3 days. The mild inflammatory response, typically seen in rats and in incisional wounds, precluded large numbers of macrophages at the wound edge. An occasional macrophage, however, contained SPARC mRNA (Figure 2i ). Figures 3a-3f illustrate immunoreactivity for TSP-1 in wounds from 12 hr to 14 days. Expression of TSP-1 protein was noted at 12 hr (Figure 3a) in the thrombus at the wound edge. The immunoreactivity was extracellular and was not associated with a singular cell type. The intensity of stain along the wound edge increased be-1 d Figure 5 . Expression of SPARC in wound repair by in situ hybridization. In the darkfield micrographs the epidermis is along the left side. Shown are representative photographs of the wounds at (a) 1, (b) 2, (c) (d) 5, (e) 7, and (1) 14 days after in situ hybridization with a SPARC riboprobe. At 1 (a) and 2 days (b) there was expression of SPARC mRNA in the normal dermis (open arrows) and in the thrombus (white arrows) but not at the wound edge (black arrows). At 3 days (c) SPARC mRNA was apparent at the wound edge (black arrows) but was minimal in adjacent regions (arrowheads). The expression of SPARC mRNA at the wound edge (black arrows) continued to increase at 5 days (d) and was maximal at 7 days (a). By 14 days (f) the signal was less localized at the wound edge. Bar = 200 pm. tween 1 and 2 days (Figures 3a and 3c ), decreased at 3 days ( Figure  3d ), and was no longer detectable from 5 to 14 days (Figures 3a  and 3f ). Quantitative analysis of TSP-1 expression showed maximal reaction product at the wound edge at 1-2 days (data not shown).
Spatial and Temporal Distribution of T S R
Normal epidermis and dermis did not stain for TSP-1. In this model, some of the endothelial cells in the capillaries and arterioles of normal and injured dermis exhibited immunoreactivity. Hair follicles expressed TSP-1 protein at all timepoints. Figures 6 a -6~ show wound tissues at 1,5, and 14 days subjected to in situ hybridization for TSP-1 "A.
Photographs were taken in an identical manner as those for SPARC and Type I collagen. Although there was a low level of expression of TSP-1 mRNA throughout the dermis, there was no detectable change in the expression of TSP-1 mRNA at the wound edge at any of the timepoints. TSP-1 mRNA was, however, noted in the thrombus in the early wound (Figure 6a ). This result was consistent with the immunoreactivity in the thrombus noted by immunohistochemistry. An occasional hair follicle expressed TSP-1 mRNA (data not shown). The TSP-1 riboprobe did not crossreact with TSP-2 or TSP-3 as demonstrated by differential expression in mouse embryos (hela-Arispe et al., in press) . Although macrophages might have contributed to the positive signal for TSP-1 in the thrombus at the early timepoints, a combination of in situ hybridization and immunohistochemistry with the TSP-1 riboprobe and the ED-1 antibody revealed no macrophages at the wound edge that definitively expressed TSP-1 mRNA in this model (data not shown).
Discussion
The incisional wound healing model in rats was chosen because it provided a local, active repair process associated with rapid cell migration, proliferation, and formation of granulation tissue. The area of tissue remodeling at the incision site was the focal point for analysis of the expression of SPARC and TSP-1 in wound repair.
Earlier studies of SPARC expression have emphasized its presence in tissues that exhibit high rates of proliferation and morphological change, such as the developing mouse embryo (Sage et al., 1989~; Holland et al., 1987) . In an adult animal an analogous condition occurs with the rapid changes required of a tissue undergoing wound repair (ffrench-Constant et al., 1989) . In addition to the proliferative and morphological changes similar to embryogenesis, cells involved in wound healing are affected by mediators of the inflammatory response that are associated with repair of tissues. In this study the distribution of SPARC mRNA and protein during wound repair was consistent with results from prior studies of this protein in vitro and in vivo. The presence of SPARC mRNA in the thrombus was not an unexpected result, as platelets are a rich source of SPARC protein and megakaryocytes synthesize SPARC mRNA (Villarreal et al., 1991) . Our results provide evidence that platelets contain detectable levels of SPARC mRNA; others have shown that platelets are repositories for mRNA encoding a variety of other megakaryocyte gene products that include platelet factor 4, GMP-140, and thrombospondin (Johnston et al., 1990; Sottile et al., 1989) . The absence of SPARC protein in the wound clot at 12 hr was consistent with the rapid degradation of SPARC released from the a-granules of platelets activated by thrombin (Stenner et al., 1986) . SPARC is a "culture shock" protein expressed when cells are cultured under conditions of stress (Sage et al., 1984) . The synthesis of this protein is also increased in chondrocytes exposed to heat shock in vitro (Neri et al., 1992) . In wound repair in vivo, the expression of SPARC mRNA and protein in fibroblastic cells at the wound edge, first detected at Day 2, correlated with the increase in inflammatory activity after an injury. As expected, the inflammatory influx of macrophage-like cells and white blood cells into the tissue was maximal at 2 to 3 days. Combined immunohistochemistry and in situ hybridization confirmed that macrophages were present and that a few of these cells expressed SPARC "A.
Moreover. macrophages might have contributed to the positive signal for SPARC mRNA in the thrombus at the early timepoints. Although others have demonsuated an abundance of SPARC protein in atherosclerotic plaques and suggested that SPARC protein was present in macrophages (Raines et al., 1992) , the localization of SPARC mRNA in macrophages has not been previously published. Therefore, this study provides the f i published demonstration of SPARC mRNA in macrophages, a result consistent with this cell type as another source of SPARC in injured tissues. After the inflammatory response diminished, the continued expression of SPARC protein and mRNA by fibroblastic cells from Days 5-14 of wound repair is consistent with its proposed role in tissue remodeling. In vitro, SPARC has anti-adhesive properties that enhance shape changes in endothelial cells and fibroblasts (Sage et al., 1989bJ992) . These properties could facilitate closure of the wound and incorporation of the wound edge into the uninjured dermis.
SPARC is a major secretory product of platelets and exhibits affinities for Ca*+, platelet-derived growth factor, and components of the ECM, e.g., Type I collagen (Raines et al., 1992; Sage et al., 1989b; Engel et al., 1987) . The co-expression of SPARC and Type I collagen in fibroblasts has been described in cell culture and in tissues (Vuorio et al., 1991; Salonen et al., 1990) . In our studies, fibroblastic cells in the normal dermis expressed both of these proteins, although relatively fewer cells were immunoreactive for SPARC. By in situ hybridization, the mRNA for SPARC and Type I collagen had similar patterns of expression at all timepoints during wound repair. TGF-Pl, a cytokine that exhibits increased expression during wound repair and enhances wound healing, has been shown to augment SPARC and Type I collagen mRNA and protein synthesis by dermal fibroblasts (Pierce et al., 1992; Mustoe et al., 1987;  and manuscript submitted for publication). In wound healing, TGFPl might increase the production of structural proteins, such as Type I collagen, in concert with versatile anti-adhesive matrix components, such as SPARC, that can enhance cell shape changes and motility (Hasselaar and Sage, 1992) .
Like SPARC, TSP-1 is important in cell-cell and cell-matrix interactions. TSP-1 was first described as a component of platelet a-granules that appeared to facilitate platelet aggregation (Lawler et al., 1978) . Prior work on the appearance of TSP (presumably TSP-1) in wound tissue indicated that it was deposited at the wound edge early in the repair process (Raugi et al., 1987) . We corroborate these results. The expression of TSP-1 protein and mRNA in the wound clot indicates but does not prove a function for this protein in thrombus formation. The identification of mRNA for TSP-1 in the clot is consistent with its presence in macrophages (Botney et al., 1992; Watkins et al., 1990; Jaffe et al., 1985) and platelets (Sot-tile et al., 1989) . As controls for the detection of SPARC and TSP-1 mRNA in the thrombus, we found no detectable hybridization with the respective sense riboprobes and the thrombus was not labeled with the riboprobe for Type I collagen, a protein not usually associated with platelets or macrophages. In contrast to SPARC, the extracellular appearance of TSP-1 by immunohistochemistry, the rapid disappearance of the protein as the wound re-epithelialized, and the absence of detectable changes in TSP-1 mRNA at the wound edge by in situ hybridization indicate that this protein is a by-product of components of the early hemostatic plug rather than a de novo product of cells in the wound. As TSP-1 has been shown to decrease focal adhesions in endothelial cells (Murphy-Ullrich and Hook, 1989) and permits attachment, but not spreading, of several cell types (Lawler et al., 1988) , its early appearance at the wound edge might facilitate cell remodeling in the dermis in vivo. Furthermore, TSP-1 binds n;Fp (Murphy-Ullrich et al., 1992) and activates latent forms of this cytokine (Schultz-Cherry et al., 1993) . As the latter is important in wound repair and increases the expression of Type I collagen and SPARC by dermal fibroblasts, it is reasonable that, in the early stages of wound repair, TSP-1 might enhance local levels of TGFp, which in turn would induce other components of the ECM. The expression of TSP-1 protein at the wound edge began to decrease at 3 days, when the inflammatory response was maximal, and was not detected at later times. Macrophages contain TSP-1 (Botney et al., 1992; Watkins et al., 1990; JafYe et al., 1985) and might have contributed to the positive signal in the thrombus at the early timepoints. However, in the absence of a vigorous inflammatory response we did not identify TSP-1 mRNA in macrophages at the wound edge by combined immunohistochemistry and in situ hybridization.
Angiogenesis is an important component of wound healing after the initial stages of coagulation and inflammation. In a model of angiogenesis in vitro, there was increased expression of SPARC mRNA and protein when bovine aortic endothelial cells grew from confluency into cultures that contained cord-like structures with patent lumina (Iruela-Arispe et al., 1991b) . In vivo, SPARC has been detected in newly-formed vessels in the developing embryo and at sites of injury (Raines et al., 1992;  and manuscript submitted for publication). Furthermore, SPARC and/or fragments of SPARC are angiogenic in vitro and in vivo (manuscript submitted for publication). In the present studies, capillaries and arterioles in the normal and injured areas of the dermis expressed SPARC protein at all stages of wound repair. In contrast, TSP-1 is anti-angiogenic in vitro and in vivo (hela-Arispe, 1991a; Good et al., 1990) . Moreover, the addition of SPARC protein to endothelial cells undergoing angiogenesis in vitro further decreased their expression of TSP-1 mRNA . In the context of this study, the early, transient expression of TSP-1 followed by the later, more persistent expression of SPARC is consistent with a differential role for SPARC and TSP-1 in the regulation of angiogenic stimuli in wound repair. During the initial phase of repair which is dependent on coagulation and inflammation, the presence of an antiangiogenic protein (e.g., TSP-1) might be beneficial. In subsequent stages of wound repair, the presence of extracellular proteins that facilitate angiogenesis (e.g., SPARC) might enhance the formation of granulation tissue.
Because of their temporal and spatial distribution in an animal model of wound healing, we propose that SPARC and TSP-1 play significant but different roles in wound repair. The expression of SPARC and TSP-1 in wound repair is consistent with prior work performed in cell culture and in other tissues, but our study has provided the first model that compares the expression of both the mRNA and protein of these components in vivo. SPARC was secreted de novo by cells at the wound site and exhibited increased expression as the wound healed this result is consistent with the ability of SPARC to augment changes in cell responses that mediate the formation of granulation tissue and the remodeling required throughout the healing process. In contrast, TSP-1 was transiently deposited near the site of injury as a product of activated platelets, and possibly macrophages, at the wound site. TSP-1 was not synthesized by cells in the wound and was not detected in the later stages of wound repair. Since TSP-1 facilitates hemostasis through its interaction with fibrin in the thrombus and is, moreover, antiangiogenic, its transient deposition at the wound edge could provide a provisional mauix that catalyzes the induction of cell proliferation by cytokines and the establishment of a permanent matrix for wound repair.
